VYGR: חוב כולל להון Voyager Therapeutics, Inc.

The Voyager Therapeutics (VYGR) market valuation chart on the GURU.Markets platform shows that the debt-to-equity ratio is 0.22. The business develops brain gene correction methods via the TRACER system, whose patents for drug delivery into CNS tissues force market leaders to purchase licenses. Such a technological gap makes entry for new players virtually impossible. However, sanctions and geopolitical conflicts are currently hindering international trials and logistics.

Portfolio managers are closely monitoring the financing structure of Voyager Therapeutics (VYGR). This ratio compares total debt obligations to net assets, determining the business's level of dependence on external borrowing. By analyzing the total liability-to-equity ratio, investors assess the risk of insolvency. For a company with high R&D expenses and no revenue, this indicator reflects the rate of cash burn. An upward trend in the curve signals a dangerous increase in the debt load.